Integral Health Asset Management, LLC Myovant Sciences Ltd. Transaction History

Integral Health Asset Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 12, 2022	SELL	$11.38 - $16.4 $284,500 - $409,999	-25,000 Closed	0 $0
Q4 2021 Feb 02, 2022	SELL	$14.31 - $23.87 $572,400 - $954,800	-40,000 Reduced 61.54%	25,000 $389,000
Q3 2021 Nov 12, 2021	SELL	$18.94 - $26.99 $378,800 - $539,800	-20,000 Reduced 23.53%	65,000 $1.46 Million
Q2 2021 Aug 30, 2021	SELL	$17.07 - $24.56 $1.45 Million - $2.09 Million	-85,000 Reduced 50.0%	85,000 $1.94 Million
Q2 2021 Aug 13, 2021	BUY	$17.07 - $24.56 $1.79 Million - $2.58 Million	105,000 Added 161.54%	170,000 $3.87 Million
Q1 2021 May 10, 2021	BUY	$20.46 - $25.18 $306,900 - $377,700	15,000 Added 30.0%	65,000 $1.34 Million
Q3 2020 Nov 16, 2020	BUY	$14.05 - $22.6 $702,500 - $1.13 Million	50,000 New	50,000 $703,000

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Integral Health Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Integral Health Asset Management, LLC with notifications on news.